← ALNYLAM PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($410.1m) | ($490.9m) | ($761.5m) | ($886.1m) | ($858.3m) | ($852.8m) | ($1.1b) | ($440.2m) | ($278.2m) | $313.7m | — | |
| Depreciation, Depletion and Amortization | $15.1m | $13.4m | $6.4m | $17.2m | $34.8m | $47.6m | $44.5m | $54.1m | $56.7m | $55.7m | $54.8m | |
| Depreciation | $9.6m | $11.9m | $12.8m | $16.6m | $30.2m | $36.8m | $39.1m | $51.6m | $55.1m | $54.8m | $101.2m | |
| Deferred Income Tax Expense (Benefit) | — | — | ($788k) | ($2.0m) | ($3.2m) | ($2.8m) | ($1.4m) | ($713k) | ($106.8m) | ($2.2m) | ($9.6m) | |
| Share-based Payment Arrangement, Noncash Expense | $75.5m | $92.8m | $157.8m | $174.8m | $139.9m | $165.7m | $230.6m | $221.7m | $272.1m | $348.2m | $336.6m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $596k | $257k | $3.5m | — | — | — | — | — | — | — | — | |
| Share-based Payment Arrangement, Expense | — | — | — | $174.8m | $139.9m | $165.7m | $230.6m | $221.7m | $272.1m | $348.2m | $336.6m | |
| Nonoperating Income (Expense) | $14.5m | $9.2m | $54.0m | $54.2m | ($27.2m) | ($143.5m) | ($341.9m) | ($151.3m) | ($200.5m) | ($178.4m) | — | |
| Other Nonoperating Income (Expense) | $6.2m | ($3.0m) | $4.2m | $11.3m | $45.5m | ($2.0m) | ($109.4m) | ($125.7m) | ($180.6m) | $5.2m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | — | ($15.2m) | $24.2m | $56.2m | $101.8m | $45.6m | $87.9m | $86.5m | $360.0m | ($357.6m) | |
| Increase (Decrease) in Inventories | — | — | $22.6m | $32.4m | $35.4m | $26.4m | $34.1m | ($18.4m) | ($13.6m) | ($8.5m) | ($11.9m) | |
| Increase (Decrease) in Accounts Payable | $10.1m | ($4.9m) | $15.5m | — | — | — | — | — | — | — | ($39.8m) | |
| Net Cash Provided by (Used in) Operating Activities | ($307.7m) |
($382.8m)
-24.40%
|
($562.6m)
-46.98%
|
($278.4m)
+50.51%
|
($615.0m)
-120.87%
|
($641.7m)
-4.35%
|
($541.3m)
+15.65%
|
$104.2m
+119.24%
|
($8.3m)
-107.98%
|
$524.1m
+6405.10%
|
$911.8m
+73.98%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $64.6m | $104.2m | $126.9m | $140.2m | $70.4m | $76.4m | $72.1m | $62.2m | $34.3m | $58.7m | ($91.9m) | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | ($7.0m) | $1.9m | $0 | ($11.3m) | ($54.0m) | ($55.7m) | $33.3m | $16.9m | $3.0m | $2.3m | — | |
| Payments for (Proceeds from) Other Investing Activities | — | — | — | $7.0m | $5.3m | $4.2m | $4.7m | $4.4m | $117k | $2.1m | — | |
| Net Cash Provided by (Used in) Investing Activities | $142.6m | ($290.4m) | $272.9m | ($417.7m) | ($435.5m) | ($273.3m) | $169.4m | ($336.4m) | ($116.8m) | $436.3m | $74.9m | |
| Cash flows from financing activities: | ||||||||||||
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | — | ($76.6m) | $0 | $0 | ($42.5m) | — | |
| Induced Conversion of Convertible Debt Expense | — | — | — | — | — | — | — | — | — | $42.5m | — | |
| Proceeds from Issuance of Common Stock | — | $1.1b | — | $381.9m | $0 | $0 | — | — | — | — | $0 | |
| Net Cash Provided by (Used in) Financing Activities | $177.8m |
$1.1b
+532.56%
|
$65.5m
-94.18%
|
$823.2m
+1157.35%
|
$995.0m
+20.87%
|
$1.2b
+25.34%
|
$425.8m
-65.86%
|
$172.1m
-59.57%
|
$294.2m
+70.89%
|
($305.2m)
-203.75%
|
($377.0m)
-23.53%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | $0 | ($224.2m) | $127.0m | ($50.6m) | $323.1m | $46.4m | ($53.7m) | $153.8m | $690.2m | $1.7b | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $0 | $0 | ($83k) | $4.9m | ($9.0m) | ($7.4m) | $814.9m | $968.7m | $1.7b | $1.7b | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $0 | $0 | ($83k) | $4.9m | ($9.0m) | ($7.4m) | $6.4m | ($15.2m) | $34.9m | ($16.1m) | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $1.1m | $2.4m | $775k | $172k | $0 | $24.7m | $45.2m | $32.1m | $67.6m | $218.7m | — | |
| Income Taxes Paid, Net | $111k | — | — | — | — | — | — | — | $14.4m | $15.1m | — | |
| Additional Financial Items | ||||||||||||
| Equity Securities, FV-NI, Gain (Loss) | ($7.0m) | $1.9m | $3.6m | $11.3m | $54.0m | $55.7m | ($33.3m) | ($16.9m) | ($3.0m) | ($2.3m) | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | $20.6m | $0 | — | — | — | — | — | — | — | |
| General and Administrative Expense | $89.4m | $199.4m | — | — | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | — | — | $823k | $863k | $2.7m | $680k | $4.2m | $6.7m | ($99.2m) | $9.4m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $141.9m | $252.6m | — | |
| Investment Income, Interest | — | — | — | — | $11.8m | $1.6m | — | $95.6m | $122.0m | $111.5m | — | |
| Operating Expenses | $471.7m | $590.0m | — | — | — | — | — | — | — | — | — | |
| Operating Lease, Expense | — | — | — | — | $50.7m | $59.5m | $58.6m | $61.6m | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.